one patient experienced QTc prolongation.
and the follow-on, VX-667:
Failed to meet pharmacokinetic objectives in a Phase 1 trial
Posted by kinasepro on November 21, 2007
one patient experienced QTc prolongation.
and the follow-on, VX-667:
Failed to meet pharmacokinetic objectives in a Phase 1 trial
Posted in Aurora, Merck & Co., Vertex | 15 Comments »